NCT03588923已完成1 期
A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatitis C Virus infection.
详细描述
A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are 400, 600, and 800 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose;
- •18-65 years of age;
- •Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50 kg for males and ≥45 kg for females;
- •No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as Boceprevir, Telaprevir, Simeprevir, Sofosbuvir, Daclatasvir, Asunaprevir;
- •No antiviral treatment such as immune modulators, thymosin or other immune stimulating factors, interferon, or Chinese herbs in the past 6 months;
- •HCV RNA ≥10*5 IU/mL at screening (Roche COBAS Taqman);
- •Chronic genotype 1-6 HCV Infection;
- •Serum ALT ≤10 times ULN;
- •FibroScan score ≤17.5kPa within 6 months before screening or at screening, or absence of cirrhosis within 12 months before screening;
- •Subjects are capable of understanding and complying with the protocol and have signed the informed consent form.
排除标准
- •Smoke more than 5 cigarettes per day within three months prior to screening;
- •Subjects allergic to the study drug (including its excipients) or subjects who are prone to allergies;
- •History of drug and/or alcohol abuse (alcohol consumption exceeding 14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);
- •Blood donation or massive blood loss (> 450 mL) within three months prior to screening;
- •History of any non-HCV liver diseases, including but not limited to hemochromatosis, primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic hepatitis, non-alcoholic steatohepatitis, etc.;
- •Subjects with dysphagia or with any gastrointestinal disorders (or postoperative conditions) that may affect the study drug absorption;
- •Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- •Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
- •Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;
- •Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the disposition of the study drug within 2 weeks prior to screening;
- •Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone;
- •Subjects with major changes in diet or exercise habits recently;
- •Participation in other clinical trials within three months prior to enrollment;
- •Electrocardiogram abnormalities with clinical significance;
- •Laboratory tests with clinical significance or other clinical findings that indicate clinically significant diseases not associated with HCV infection (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematological, endocrine, pulmonary, psychiatric, cardiovascular diseases);
- •Pregnant or lactating women;
- •Creatinine clearance ≤ 60 mL/min;
- •Evidence of co-infection with HBV, HIV, or syphilis;
- •Child-Pugh Grade B or C;
- •Clinically significant hepatic decompensation including but not limited to, hepatic encephalopathy, hepatocellular carcinoma, variceal bleeding, ascites, etc.;
- •Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing;
- •Use of products containing alcohol within 24 hours prior to dosing;
- •Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years;
研究组 & 干预措施
Cohort 1
Active Comparator
SH229 (400 mg) or matching placebo, once daily
干预措施: SH229 (Drug)
Cohort 1
Active Comparator
SH229 (400 mg) or matching placebo, once daily
干预措施: Placebos (Drug)
Cohort 2
Active Comparator
SH229 (600 mg) or matching placebo, once daily
干预措施: SH229 (Drug)
Cohort 2
Active Comparator
SH229 (600 mg) or matching placebo, once daily
干预措施: Placebos (Drug)
Cohort 3
Active Comparator
SH229 (800 mg) or matching placebo, once daily
干预措施: SH229 (Drug)
Cohort 3
Active Comparator
SH229 (800 mg) or matching placebo, once daily
干预措施: Placebos (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: up to Day 10
Antiviral effects of SH229, as measured by HCV RNA levels
时间窗: up to Day 10
次要结局
- Area under the plasma concentration versus time curve(AUC)(up to Day 10)
- Time to peak plasma concentration(Tmax)(up to Day 10)
- Peak plasma concentration(Cmax)(up to Day 10)
- Half-life time(t1/2)(up to Day 10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial of STP0404 in Adults With HIV-1 InfectionHIV-1-infectionNCT05869643ST Pharm Co., Ltd.25
已完成
2 期
A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus InfectionsNCT03258502Pfizer66
已完成
2 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionChronic Hepatitis C Virus InfectionNCT00851890AbbVie (prior sponsor, Abbott)30
终止
2 期
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingCOVID-19NCT04396106Atea Pharmaceuticals, Inc.83
终止
2 期
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionRespiratory Syncytial Virus InfectionsNCT03656510Janssen Research & Development, LLC246